Presbyopia Pipeline

DelveInsight’s, “Presbyopia - Pipeline Insight, 2025” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Presbyopia: Understanding

Presbyopia: Overview

Presbyopia is a common, age-related refractive condition that leads to the gradual decline in the eye's ability to focus on near objects, typically becoming noticeable in the early to mid-40s and continuing to progress with age. The condition primarily arises from age-induced changes in the crystalline lens, which loses its elasticity and becomes thicker due to protein cross-linking and compaction. This reduction in lens flexibility impairs its ability to change shape effectively during accommodation, a process that enables the eye to focus on nearby objects. Additionally, the ciliary muscle, responsible for exerting pressure on the lens to adjust its curvature, weakens with age, further limiting the eye's capacity to focus on close-up tasks. While presbyopia is a natural and physiological part of the aging process, it can significantly affect an individual's quality of life by causing blurry near vision, eye strain, and headaches during close-up activities. Treatment options, such as reading glasses, multifocal lenses, contact lenses, or surgical interventions like LASIK or intraocular lens implants, can help manage the condition, allowing individuals to maintain functional vision at near distances.

It is diagnosed through a comprehensive eye exam, starting with a refraction test to assess near and distance vision, distinguishing it from other refractive errors. Visual acuity tests measure the ability to see at various distances, highlighting difficulties with near vision. A dilated eye exam allows a thorough assessment of the internal eye structures, including the lens and retina, to rule out other conditions. Slit-lamp examination provides detailed inspection of the anterior eye, where presbyopia-related changes occur. Additional tests, such as auto refraction or retinoscopy, may be used to refine the diagnosis. Regular eye exams are recommended starting in the 40s, with increased frequency as age advances.

Presbyopia treatment aims to restore near vision and reduce dependence on reading glasses, with options ranging from non-surgical aids to advanced surgical procedures. Non-surgical solutions include reading glasses, bifocals, trifocals, progressive lenses, and multifocal or monovision contact lenses. These optical corrections provide varying degrees of near, intermediate, and distance vision. Surgical treatments, such as monovision LASIK, multifocal LASIK, and photorefractive keratectomy (PRK), reshape the cornea to address presbyopia. Refractive lens exchange (RLE) and cataract surgery with multifocal intraocular lenses (IOLs) can also correct presbyopia, especially in patients with concurrent cataracts. Pharmaceutical options, such as pilocarpine eye drops, offer temporary near vision improvement by constricting the pupil.

 

"Presbyopia- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Presbyopia pipeline landscape is provided which includes the disease overview and Presbyopia treatment guidelines. The assessment part of the report embraces, in depth Presbyopia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Presbyopia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Presbyopia R&D. The therapies under development are focused on novel approaches to treat/improve Presbyopia.

 

Presbyopia Emerging Drugs Chapters

This segment of the Presbyopia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Presbyopia Emerging Drugs

• MR-141: Viatris

MR-141 is being developed by Viatris for the treatment of presbyopia. It is a 0.75% phentolamine ophthalmic solution that works by enhancing the eye's ability to focus on near objects through muscarinic receptor targeting and mild pupil constriction. This helps expand the depth of field and improves accommodation. MR-141 is being developed in collaboration with Opus Genetics and the drug is currently in Phase III stage of its clinical trial for presbyopia.

 

• GLK-302: Glaukos Corporation

Glaukos Corporation is developing GLK-302, a sterile ophthalmic topical cream containing pilocarpine, intended for the treatment of presbyopia. The cream is applied to the eyelid, facilitating the transdermal delivery of pilocarpine to the eye. Pilocarpine, a muscarinic acetylcholine receptor agonist, primarily targets the M3 and M1 receptors within the eye, inducing pupillary constriction and enhancing the depth of focus. This mechanism improves near vision in individuals with presbyopia while minimally affecting distance vision. The drug is currently in Phase II stage of its clinical trial for presbyopia.

 Further product details are provided in the report……..

 

Presbyopia: Therapeutic Assessment

This segment of the report provides insights about the different Presbyopia drugs segregated based on following parameters that define the scope of the report, such as:

• Major  Players in Presbyopia
• There are approx. 6+ key companies which are developing the therapies for Presbyopia. The companies which have their Presbyopia drug candidates in the most advanced stage, i.e. Phase III include, Viatris.

 

Phases

DelveInsight’s report covers around 6+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Presbyopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Presbyopia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Presbyopia therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Presbyopia drugs.

 

Presbyopia Report Insights

• Presbyopia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Presbyopia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Presbyopia drugs?
• How many Presbyopia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Presbyopia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Presbyopia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Presbyopia and their status?
• What are the key designations that have been granted to the emerging drugs?